Tardive dyskinesia (TD) is a serious, potentially irreversible neurologic movement disorder that can potentially be caused by any dopamine receptor-blocking agent. The most commonly implicated drugs are antipsychotics and metoclopramide, an antiemetic drug. TD is characterized by involuntary, repetitive movements, typically resulting from long-term use of the offending agents. These movements include grimacing, tongue protrusion, lip-smacking, and rapid eye blinking, but movements may also occur in the trunk and extremities. Early clinical recognition of TD is important to allow for the discontinuation of the causative drug, if possible, thereby reducing the risk of irreversibility. In addition to stopping the causative drug, other approaches for managing TD involve either switching to an alternative medication, reducing the current drug's dosage, or employing symptomatic treatments in moderate to severe cases. Symptomatic treatments most commonly include the utilization of vesicular monoamine transporter type 2 (VMAT2) inhibitors and botulinum toxin injections. For patients suffering from permanent and debilitating TD, surgical interventions, such as deep brain stimulation, may be considered as a last resort.